Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MEIP 
MEI Pharma Inc (MEIP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/10/2025: MEIP (1-star) is a SELL. SELL since 2 days. Simulated Profits (25.79%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $20
1 Year Target Price $20
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -7.32% | Avg. Invested days 39 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 100.81M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 1 | Beta 0.22 | 52 Weeks Range 1.46 - 8.25 | Updated Date 09/12/2025 |
52 Weeks Range 1.46 - 8.25 | Updated Date 09/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.75 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -23.23% | Return on Equity (TTM) -89.74% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 65750645 | Price to Sales(TTM) 0.27 |
Enterprise Value 65750645 | Price to Sales(TTM) 0.27 | ||
Enterprise Value to Revenue 1.39 | Enterprise Value to EBITDA -1.58 | Shares Outstanding 32837700 | Shares Floating 5714799 |
Shares Outstanding 32837700 | Shares Floating 5714799 | ||
Percent Insiders 14.45 | Percent Institutions 8.13 |
Upturn AI SWOT
MEI Pharma Inc
Company Overview
History and Background
MEI Pharma, Inc. is a pharmaceutical company focused on developing and commercializing novel cancer therapies. Founded in 2000, it has evolved from a research-focused organization to one with marketed products and a pipeline of drug candidates.
Core Business Areas
- Drug Development: Focuses on developing and clinical testing of cancer therapeutics.
- Commercialization: Marketing and sales of approved drugs, primarily through partnerships.
Leadership and Structure
The leadership team consists of the CEO, CFO, CMO and other executive-level positions. The organizational structure involves research and development, clinical operations, commercial operations, and administrative functions.
Top Products and Market Share
Key Offerings
- Voruciclib: An oral CDK9 inhibitor, which MEI Pharma hopes to get approval and bring to market. Competitors include companies developing other CDK inhibitors, such as Roche and Novartis.
- Zandelisib: A PI3K delta inhibitor. In July 2024, MEI Pharma entered into an asset purchase agreement with Dr. Reddy's Laboratories Inc. for Zandelisib. Competitors are other PI3K inhibitors from companies like Incyte and TG Therapeutics.
Market Dynamics
Industry Overview
The oncology market is characterized by intense competition, high research and development costs, stringent regulatory requirements, and a growing demand for targeted therapies.
Positioning
MEI Pharma operates in a competitive space, focusing on specific cancer types and leveraging partnerships for commercialization. Competitive advantages stem from novel mechanisms of action and clinical trial results.
Total Addressable Market (TAM)
The total oncology market is valued in the hundreds of billions of dollars. MEI Pharma targets specific sub-segments within this market, representing a smaller, but still significant, TAM. The company's positioning depends on the success of its clinical trials and partnerships.
Upturn SWOT Analysis
Strengths
- Innovative drug candidates
- Experienced management team
- Partnerships for commercialization
- Targeted approach to cancer therapies
Weaknesses
- Dependence on clinical trial outcomes
- Limited internal commercialization capabilities
- Small market capitalization
- Significant debt
Opportunities
- Expansion of clinical trial programs
- Securing regulatory approvals
- Establishing new partnerships
- Acquisition by larger pharmaceutical company
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent expirations
Competitors and Market Share
Key Competitors
- INCY
- TGTX
- MRTX
- ARRY
Competitive Landscape
MEI Pharma faces competition from larger pharmaceutical companies with greater resources and established market presence. MEI competes by focusing on targeted therapies and leveraging strategic partnerships.
Major Acquisitions
Plexxikon
- Year: 2020
- Acquisition Price (USD millions): 3.6
- Strategic Rationale: Acquisition of rights to ME-401, now Zandelisib
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by advancement of drug candidates through clinical trials and securing partnerships.
Future Projections: Future growth depends on successful clinical trial outcomes and commercialization efforts. Analyst estimates vary based on the potential of the pipeline.
Recent Initiatives: Focus on developing voruciclib and other pipeline candidates.
Summary
MEI Pharma is a small-cap pharmaceutical company focusing on cancer therapies. Its success hinges on the successful clinical development and commercialization of its drug candidates, particularly voruciclib. The company faces significant competition and regulatory hurdles. Strategic partnerships and financial management are critical for its long-term growth. Given the state of the company, an investment into it can be high risk, high reward.
Peer Comparison
Sources and Disclaimers
Data Sources:
- MEI Pharma SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share data are approximations based on publicly available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MEI Pharma Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2003-12-19 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 28 | Website https://meipharma.com |
Full time employees 28 | Website https://meipharma.com | ||
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.